<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573934</url>
  </required_header>
  <id_info>
    <org_study_id>UCHP-KS-2</org_study_id>
    <nct_id>NCT03573934</nct_id>
  </id_info>
  <brief_title>Gut Hormones and Bone Remodeling in Humans (KS-2)</brief_title>
  <acronym>KS-2</acronym>
  <official_title>Investigation of GLP-2 Mechanism of Action (KS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of GLP-2 and GIP on bone remodeling in healthy young men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will investigate acute effects of GLP-2 and GIP on bone remodeling in healthy young men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">March 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone resorption</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>C-terminal telopeptide (CTX) is a marker of bone resorption. Measured in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone formation</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>P1NP is a marker of bone formation. Measured in serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>PTH is a bone marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Intact and total GIP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-2</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Intact GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Bone marker.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Before blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From -10 minutes to 240 minutes.</time_frame>
    <description>Before blood sampling</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-Like Peptide-2 (GLP-2) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose-dependent Insulinotropic polypeptide (GIP) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-2+GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-2+GIP injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>GLP-2</description>
    <arm_group_label>GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>GIP</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2+GIP</intervention_name>
    <description>GLP-2+GIP</description>
    <arm_group_label>GLP-2+GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age between 20 and 40 years old Caucasian Healthy BMI between 18.5 and 24.9 kg/m2.

        Exclusion Criteria:

        Chronic disease Smoking Medication Weight change more than 3 kg whitin the last 3 months
        Overweight surgery Intestinal surgery Hgb&lt;8,0 mmol/L Decreased renal function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsa Skov-Jeppesen</investigator_full_name>
    <investigator_title>Principal Investigator.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

